<SEC-DOCUMENT>0000917520-22-000051.txt : 20221026
<SEC-HEADER>0000917520-22-000051.hdr.sgml : 20221026
<ACCEPTANCE-DATETIME>20221026061526
ACCESSION NUMBER:		0000917520-22-000051
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20221026
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221026
DATE AS OF CHANGE:		20221026

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INTEGRA LIFESCIENCES HOLDINGS CORP
		CENTRAL INDEX KEY:			0000917520
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				510317849
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26224
		FILM NUMBER:		221331008

	BUSINESS ADDRESS:	
		STREET 1:		1100 CAMPUS ROAD
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
		BUSINESS PHONE:		6092750500

	MAIL ADDRESS:	
		STREET 1:		1100 CAMPUS ROAD
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTEGRA LIFESCIENCES CORP
		DATE OF NAME CHANGE:	19950614
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>iart-20221026.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:852baafa-ae93-41e4-ab78-70b4172d0966,g:7a16c048-5b07-4688-8d13-bd45fd1dd359,d:65de8900cb174a6d8abd1268583bbd51--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>iart-20221026</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV80L2ZyYWc6ZDBjMDJmNTVhYzZjNDAwZGFmY2FjYjU2N2JmNWJmNzgvdGFibGU6MjI0NmZmODIyYjg2NDUwYWFkOTljOGEzNDNjOGUzYjgvdGFibGVyYW5nZToyMjQ2ZmY4MjJiODY0NTBhYWQ5OWM4YTM0M2M4ZTNiOF8yLTEtMS0xLTEzNTI0NQ_74e260f9-2010-45ce-81c4-bd6bc6c7e129">0000917520</ix:nonNumeric><ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV80L2ZyYWc6ZDBjMDJmNTVhYzZjNDAwZGFmY2FjYjU2N2JmNWJmNzgvdGFibGU6MjI0NmZmODIyYjg2NDUwYWFkOTljOGEzNDNjOGUzYjgvdGFibGVyYW5nZToyMjQ2ZmY4MjJiODY0NTBhYWQ5OWM4YTM0M2M4ZTNiOF81LTEtMS0xLTEzNTI0NQ_e2ef3880-557e-4d7a-b872-3c05e5e340ad">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="iart-20221026.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000917520</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-26</xbrli:startDate><xbrli:endDate>2022-10-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i65de8900cb174a6d8abd1268583bbd51_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%">Washington, D.C. 20549 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzQw_b5f13318-25d8-4db0-9155-d372aa25f9af">8-K</ix:nonNumeric> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18yMzM_5a06e638-ee7d-4c06-bf4e-ba702a3bde96">October 26, 2022</ix:nonNumeric> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzQ2_537041c9-8b88-4009-99ac-ddeca527d403">INTEGRA LIFESCIENCES HOLDINGS CORP</ix:nonNumeric>ORATION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in its Charter) </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.023%"><tr><td style="width:1.0%"></td><td style="width:40.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.686%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGFibGU6Y2FkZjhkZTNkOWNiNGI5YmFjNDIzZjRmYTM2Mjc2NDEvdGFibGVyYW5nZTpjYWRmOGRlM2Q5Y2I0YjliYWM0MjNmNGZhMzYyNzY0MV8wLTAtMS0xLTEzNTI0NQ_6390f7b2-8dc4-445c-992f-beef6c207243">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGFibGU6Y2FkZjhkZTNkOWNiNGI5YmFjNDIzZjRmYTM2Mjc2NDEvdGFibGVyYW5nZTpjYWRmOGRlM2Q5Y2I0YjliYWM0MjNmNGZhMzYyNzY0MV8wLTEtMS0xLTEzNTI0NQ_e96dae3c-7845-4e33-9080-9112607283b1">0-26224</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGFibGU6Y2FkZjhkZTNkOWNiNGI5YmFjNDIzZjRmYTM2Mjc2NDEvdGFibGVyYW5nZTpjYWRmOGRlM2Q5Y2I0YjliYWM0MjNmNGZhMzYyNzY0MV8wLTItMS0xLTEzNTI0NQ_79424c87-a85c-491b-9b40-a427777221e3">51-0317849</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of  Incorporation or Organization) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzQ3_70d10cbe-c75c-4b2c-a096-ed3f2bd9435e">1100 Campus Road</ix:nonNumeric>  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzQx_e92c44f7-7951-4652-a361-62d6ab14d5d2">Princeton</ix:nonNumeric>, <ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzM1_3343047e-11f4-494c-847f-b0b396ea0ad3">NJ</ix:nonNumeric> <ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzQy_d8a16384-0c70-486c-b717-6f4ba66409d9">08540</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip Code) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzM2_dc4703fe-35ac-4cbd-ad63-53c52091690b">609</ix:nonNumeric>) <ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzM3_379ae72c-811d-4aaa-8f30-bea4ec6d1592">275-0500</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report) </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzQz_4e33a390-06b6-46c8-bc0f-7a2bcf6840b0">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzM4_094ebcea-7441-402c-b234-05aff66ac7e0">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzM5_f170fb45-968a-436e-b7dc-26a823c385a0">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR   240.14d-2(b)).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzQ0_f377c343-1316-4e8d-9e3a-5feb6dafa3a8">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).</span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities Registered Pursuant to Section12(b) of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">  </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGFibGU6NjJmODRhMjZlYmI3NGNiMzlkM2ExY2VhNjljMWIzZGUvdGFibGVyYW5nZTo2MmY4NGEyNmViYjc0Y2IzOWQzYTFjZWE2OWMxYjNkZV8xLTAtMS0xLTEzNTI0NQ_4b0977b4-a37a-4eba-b188-4cf4985c71d7">Common Stock, Par Value $.01 Per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGFibGU6NjJmODRhMjZlYmI3NGNiMzlkM2ExY2VhNjljMWIzZGUvdGFibGVyYW5nZTo2MmY4NGEyNmViYjc0Y2IzOWQzYTFjZWE2OWMxYjNkZV8xLTEtMS0xLTEzNTI0NQ_8b175031-6398-46a6-a1a0-bac1adfc2918">IART</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGFibGU6NjJmODRhMjZlYmI3NGNiMzlkM2ExY2VhNjljMWIzZGUvdGFibGVyYW5nZTo2MmY4NGEyNmViYjc0Y2IzOWQzYTFjZWE2OWMxYjNkZV8xLTItMS0xLTEzNTI0NQ_ccce8746-dbb0-4f0c-b291-48c522156667">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzQ1_76682b62-fdd0-4c73-a179-bfb3672983e1">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i65de8900cb174a6d8abd1268583bbd51_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On October 26, 2022, Integra LifeSciences Holdings Corporation (the &#8220;Company&#8221;) issued a press release announcing financial results for the quarter ended September 30, 2022 (the &#8220;Press Release&#8221;). A copy of the Press Release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item. In the financial statements portion of the Press Release, the Company has included a reconciliation of GAAP revenues to organic revenues for the quarters ended September 30, 2022 and 2021, GAAP net income to adjusted earnings before interest, taxes, depreciation and amortization (&#8220;EBITDA&#8221;) for the quarters ended September 30, 2022 and 2021, GAAP net income to adjusted net income for the quarters ended September 30, 2022 and 2021, GAAP earnings per diluted share to adjusted earnings per diluted share for the quarters ended September 30, 2022 and 2021, and GAAP operating cash flow to free cash flow and adjusted free cash flow conversion used by management for the quarters and twelve months ended September 30, 2022 and 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the Press Release, the Company provided forward-looking guidance regarding adjusted earnings per diluted share but did not provide a reconciliation to GAAP earnings per share, because certain GAAP expense items are highly variable and management is unable to predict them with reasonable certainty and without unreasonable effort. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in Item 2.02 of this Current Report on Form 8-K (including the Press Release and selected historical financial information) is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section. The information contained in Item 2.02 of this Current Report on Form 8-K (including the Press Release and selected historical financial information) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Discussion of Adjusted Financial Measures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted net income, adjusted earnings per diluted share, free cash flow and adjusted free cash flow conversion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures and discontinuances.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation and amortization; (ii) other income (expense); (iii) interest income and expense; (iv) income tax expense (benefit); and (v) those operating expenses also excluded from adjusted net income.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The measure of adjusted net income consists of GAAP net income, excluding: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) EU Medical Device Regulation-related charges; (iv) intangible asset amortization expense; and (v) income tax impact from adjustments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The measure of free cash flow consists of GAAP net cash provided by operating activities less purchases of property and equipment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The adjusted free cash flow conversion measure is calculated by dividing free cash flow by adjusted net income. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company believes that the presentation of organic revenues and the various adjusted EBITDA, adjusted net income, adjusted earnings per diluted share, free cash flow and adjusted free cash flow conversion measures provides important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. Management uses non-GAAP financial measures in the form of organic revenues, adjusted EBITDA, adjusted net income, adjusted earnings per diluted share, free cash flow and adjusted free cash flow conversion when evaluating operating performance because we believe that the inclusion or exclusion of the items described below, for which the amounts and/or timing may vary significantly depending upon the Company's divestiture, acquisition, integration, and restructuring activities, for which the amounts are non-cash in nature, or for which the amounts are not expected to recur at the same magnitude, provides a supplemental measure of our operating results that facilitates comparability of our financial condition and operating performance from period to period, against our business model objectives, and against other companies in our industry. We have chosen to provide this information to investors so they can analyze our operating results in the same way that management does and use this information in their assessment of our core business and the valuation of our Company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Organic revenues, adjusted EBITDA, adjusted net income, adjusted earnings per diluted share, free cash flow and adjusted free cash flow conversion are significant measures used by management for purposes of:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; supplementing the financial results and forecasts reported to the Company's board of directors;</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; evaluating, managing and benchmarking the operating performance of the Company;</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; establishing internal operating budgets;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; determining compensation under bonus or other incentive programs;</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; enhancing comparability from period to period;</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; comparing performance with internal forecasts and targeted business models; and</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226; evaluating and valuing potential acquisition candidates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The measure of organic revenues that we report reflects the increase in total revenues for the quarter ended September 30, 2022 adjusted for the effects of currency exchange rates, revenues from acquisitions, revenues from divested products, and product discontinuations on current period revenues. We provide this measure because changes in foreign currency exchange rates can distort our reduction favorably or unfavorably, depending upon the strength of the U.S. dollar in relation to the various foreign currencies in which we generate revenues. We generate significant revenues outside the United States in multiple foreign currencies. We believe this measure provides useful information to determine the success of our international selling organizations in increasing sales of products in their local currencies without regard to fluctuations in currency exchanges rates, which we do not control. Additionally, significant divestitures, acquisitions and discontinued product lines can distort our current period revenues when compared to prior periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The measure of adjusted net income reflects GAAP net income adjusted for one or more of the following items, as applicable:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt;text-decoration:underline">Structural optimization charges.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> These charges, which include employee severance and other costs associated with exit or disposal of facilities, costs related to transferring manufacturing and/or distribution activities to different locations, and rationalization or enhancement of our organization, existing manufacturing, distribution, administrative, functional and commercial infrastructure. Some of these cost-saving and efficiency-driven activities are identified as opportunities in connection with acquisitions that provide the Company with additional capacity or economies of scale. Although recurring in nature, given management's ongoing review of the efficiency of our organization and structure, including manufacturing, distribution and administrative facilities and operations, management excludes these items when evaluating the operating performance of the Company because the frequency and amount of such charges vary significantly based on the timing and magnitude of the Company's rationalization activities and are, in some cases, dependent upon opportunities identified in acquisitions, which also vary in frequency and magnitude.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt;text-decoration:underline">Acquisition, divestiture and integration-related charges.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Acquisition, divestiture and integration-related charges include (i) inventory fair value purchase accounting adjustments, (ii) changes in the fair value of contingent consideration after the acquisition date, (iii) costs related to acquisition integration, including systems, operations, retention and severance, (iv) legal, accounting, banking and other outside consultants expenses directly related to acquisitions or divestitures, and (v) gain or loss on sale of business and related costs to complete the divestiture of business. Although recurring, given the ongoing character of our acquisitions and divestitures, these charges are not factored into the evaluation of our performance by management after completion because they are of a temporary nature, they are not related to our core operating performance and the frequency and amount of such charges vary significantly based on the timing and magnitude of our acquisition and divestiture transactions as well as the level of inventory on hand at the time of acquisition.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt;text-decoration:underline">EU Medical Device Regulation charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. These charges represent costs specific to complying with the medical device reporting regulations and other requirements of the European Union&#8217;s regulation for medical devices. Management excludes this item when evaluating the Company&#8217;s operating performance because these costs incurred are not reflective of its ongoing operations.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt;text-decoration:underline">Intangible asset amortization expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Management excludes this item when evaluating the Company's operating performance because it is a non-cash expense.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt;text-decoration:underline">Income tax impact from adjustments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Estimated impact on income tax expense related to the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.07pt">Adjustments to income tax expense for the amount of additional tax expense that the Company estimates that it would record if it used non-GAAP results instead of GAAP results in the calculation of its tax provision, based on the statutory rate applicable to jurisdictions in which the above non-GAAP adjustments relate.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ii).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:3.3pt">When we calculate the adjusted tax rate, we include a full year estimate for all discrete items. We then apply that full year rate to the year-to-date results and calculate the current quarter&#8217;s rate to arrive at the year-to-date adjusted tax rate. We believe this removes significant variability in our results and creates a more operationally consistent result for our investors to use for comparability purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the Press Release, the Company provided forward-looking guidance regarding adjusted earnings per diluted share, but did not provide a reconciliation to GAAP earnings per share, because certain GAAP expense items are highly variable and management is unable to predict them with reasonable certainty and without unreasonable effort. Specifically, the financial impact and timing of divestitures, acquisitions, integrations, structural optimization and efforts to comply with the EU Medical Device Regulation are uncertain, depend on various dynamic factors and are not reasonably ascertainable at this time. These expense items could have a material impact on GAAP results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Organic revenues, adjusted EBITDA, adjusted net income, adjusted earnings per diluted share, free cash flow and adjusted free cash flow conversion are not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the revenues, costs or benefits associated with the operations of the Company's business as determined in accordance with GAAP. As a result, you should not consider these measures in isolation or as a substitute for analysis of the Company's results as reported under GAAP. The Company expects to continue to acquire businesses and product lines and to incur expenses of a nature similar to many of the non-GAAP adjustments described above, and exclusion of these items from its adjusted financial measures should not be construed as an inference that all of these revenue adjustments or costs are unusual, infrequent or non-recurring. Some of the limitations in relying on the adjusted financial measures are:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">The Company periodically acquires other companies or businesses, and we expect to continue to incur acquisition-related expenses and charges in the future. These costs can directly impact the amount of the Company's available funds or could include costs for aborted deals which may be significant and reduce GAAP net income.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">All of the adjustments to GAAP net income have been tax affected at the Company's actual tax rates. Depending on the nature of the adjustments and the tax treatment of the underlying items, the effective tax rate related to adjusted net income could differ significantly from the effective tax rate related to GAAP net income.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the financial tables portion of the Press Release, the Company has included a reconciliation of GAAP reported revenues to organic revenues for the quarters ended September 30, 2022 and 2021 and GAAP net income to adjusted EBITDA, GAAP net income to adjusted net income, GAAP earnings per diluted share to adjusted earnings per diluted share, and GAAP operating cash flow to free cash flow and adjusted free cash flow conversion used by management for the quarters and twelve months ended September 30, 2022 and 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Exhibits</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1 </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex991-q32022earningsrelease.htm">Press Release with attachments, dated October 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex991-q32022earningsrelease.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex991-q32022earningsrelease.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex991-q32022earningsrelease.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex991-q32022earningsrelease.htm">, issued by Integra LifeSciences Holdings Corporation</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">104 Cover Page Interactive Data File (embedded within the inline XRBL document) </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i65de8900cb174a6d8abd1268583bbd51_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INTEGRA LIFESCIENCES HOLDINGS CORPORATION</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  October 26, 2022</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;/s/ Carrie Anderson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrie Anderson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:279pt;text-indent:-279pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-q32022earningsrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1a9392f145f84b03bf99691009d6f5d0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">News Release</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:120%">Integra LifeSciences Reports Third Quarter 2022 Financial Results</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">PRINCETON, N.J., October 26, 2022 - </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Integra LifeSciences Holdings Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (NASDAQ&#58; IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2022.</font></div><div style="margin-bottom:10pt;margin-top:5pt"><font><br></font></div><div style="margin-bottom:10pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Third Quarter 2022 Highlights</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Third quarter revenues of  $385 million decreased 0.4% on a reported basis and increased 3.5% on an organic basis compared to the prior year. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Third quarter GAAP earnings per diluted share of $0.60, compared to $0.51 in the prior year&#59; adjusted earnings per diluted share of $0.86, compared to $0.86 in the prior year.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">The Company completed the sale of its non-core traditional wound care (&#8220;TWC&#8221;) business at the end of August 2022.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">The Company is raising its earnings per share outlook to a range of $3.29 to $3.33 and reaffirming its full-year 2022 revenue guidance at the midpoint of its prior guidance with a tightened range of $1,551 million to $1,563 million.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The revenue range represents reported growth of 0.5% to 1.3%, inclusive of the divestiture of the TWC business and an updated foreign currency outlook, with organic growth of 3.7% to 4.5%. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;We are pleased with our sales performance in the third quarter. Our diverse portfolio continues to deliver solid, profitable growth for our shareholders,&#8221; said Jan De Witte, Integra&#8217;s president and chief executive officer. &#8220;We continue to see strong demand for our products globally and are focused on our execution in achieving our short- and long-term targets.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Third Quarter 2022 Consolidated Performance</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total reported revenues of $385.2 million decreased 0.4% on a reported basis and increased 3.5% on an organic basis compared to the prior year. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company reported GAAP gross margin of 61.5%, compared to 62.7% in the third quarter of 2021. Adjusted gross margin was 66.7%, compared to 68.3% in the prior year.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adjusted EBITDA for the third quarter of 2022 was $105.3 million, or 27.3% of revenue, compared to $104.3 million, or 27.0% of revenue, in the prior year. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Company reported GAAP net income of $49.9 million, or $0.60 per diluted share, in the third quarter of 2022, compared to a GAAP net income of $43.2 million, or $0.51 per diluted share, in the prior year. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adjusted net income for the third quarter of 2022 was $71.7 million, or $0.86 per diluted share, compared to $73.1 million, or $0.86 per diluted share, in the prior year.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Third Quarter 2022 Segment Performance</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Codman Specialty Surgical (&#126;65% of Revenues)  </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">Total revenues were $249.8 million, representing reported decline of 2.6% and organic growth of 1.6% compared to the third quarter of 2021, driven by strength in both advanced energy and CSF management partially offset by the impact of the CereLink&#174; recall in neuro monitoring.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Tissue Technologies (&#126;35% of Revenues)</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">Total revenues were $135.4 million, representing reported growth of 3.9% and organic growth of 7.2% compared to the third quarter of 2021, driven by sales of Integra skin, amniotics and ACell MicroMatrix&#174;. </font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Key Products and Business Highlights</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Advancing Key Products</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:13.8pt">Return-to-market plans for the CereLink ICP monitor are progressing, targeting first half of 2023.</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">Third quarter results include a $1.5 million recall returns provision and a $0.8 million rework accrual in cost of goods sold, both of which impacted gross margin.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Expanded the CUSA&#174; Clarity portfolio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">CUSA Clarity extended laparoscopic tip launched in the U.S., bringing the benefits of ultrasonic ablation technology to minimally invasive laparoscopic liver procedures.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.75pt">CUSA single-sided bone tip received 510(k) approval. Commercial launch is expected in the first quarter of 2023. </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">Advanced the science for the Aurora&#174; Surgiscope&#174; with the publication, in Operative Neurosurgery, of the first peer-reviewed journal article</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Aurora Surgiscope is intended for use in neurosurgery and endoscopic neurosurgery and pure neuroendoscopy (i.e., ventriculoscopy) for visualization, diagnostic and&#47;or therapeutic procedures such as ventriculostomies, biopsies and removal of cysts, tumors and other obstructions.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Business Highlights</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:13.8pt">Completed the previously announced sale of the non-core TWC business to Gentell, LLC for $28.8 million, which consists of $27.8 million in cash plus $1.0 million in contingent consideration which may be received upon achieving certain revenue-based performance milestones. The transaction included the sale of the Company's TWC products, such as sponges, gauze and conforming bandages, and certain advanced wound care dressings, such as supportive, calcium alginate, hydrogel, and foam dressings.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:13.8pt">Issued our inaugural Environmental, Social and Governance (ESG) report</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> The report highlights 2021 performance in key areas such as employee health and safety, diversity and inclusion, community impact, ethics and compliance, and environmental responsibility. The report also includes the company&#8217;s ESG strategy and roadmap to long-term sustainability.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:13.8pt">Appointed two new key executives </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:13.75pt">Harvinder Singh, EVP &#38; President, International, based in Singapore with a focus on setting and executing product-market strategies and building out Integra&#8217;s local commercial capabilities in international markets.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:13.75pt">Mark Jesser, CVP &#38; Chief Digital Officer, based in our Princeton, N.J. headquarters with a focus on partnering with our commercial, strategic marketing and business development teams to define and execute digital proposition strategies that enhance Integra&#8217;s device portfolio and its positioning within the digital health ecosystem. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Balance Sheet, Cash Flow and Capital Allocation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company generated cash flow from operations of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$68 million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the quarter. Net debt at the end of the quarter was </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$1.04 billion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and the consolidated total leverage ratio was 2.4x.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of quarter end, the Company had total liquidity of approximately </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$1.75 b</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">illion, including approximately </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$512 million </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in cash and the remainder available under the revolving credit facility.</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">2022 Outlook</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">For the full year 2022, the Company is reaffirming its revenue expectations at the midpoint of its August 2022 guidance with a tightened range of  $1,551 million to $1,563 million.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The revenue range represents reported growth of 0.5% to 1.3%, inclusive of the divestiture of the TWC business and an updated foreign currency outlook, with organic growth of 3.7% to 4.5%. Our guidance reflects our solid revenue performance through the first 9 months while considering the macro environment, continuing supply constraints, and potential adjustments to the CereLink </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">reserve.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Full-year 2022 reported revenue guidance reflects an additional 25 basis points of unfavorable foreign currency impact relative to guidance provided in August 2022. Foreign currency is now expected to unfavorably impact full year reported growth by approximately 250 basis points compared to the prior year due to the continuing strength of the US Dollar. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Full year 2022 adjusted EPS guidance is being raised to a range of $3.29 to $3.33, an increase of $0.15 at the mid-point compared to the Company&#8217;s August guidance. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">For the fourth quarter 2022, the Company expects reported revenues in the range of $391 million to $403 million, representing reported growth of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">-3.5% to -0.6%</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and organic growth of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.3% to 4.3%.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> Adjusted earnings per diluted share is expected to be in a range of $0.87 to $0.91. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Company&#8217;s guidance for fourth quarter and full-year organic sales growth excludes acquisitions and divestitures, the effects of foreign currency and the year-over-year change in revenue from discontinued products. Organic growth includes ACell as of January 20, 2022 and excludes sales from the TWC divestiture as of September 1, 2022. Adjusted earnings per share guidance reflects the impact of the divestiture of the TWC business as well as an updated foreign currency outlook. </font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Conference Call and Presentation Available Online</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Integra has scheduled a conference call for 8&#58;30 a.m. ET on Wednesday, October 26, 2022, to discuss third quarter 2022 financial results, and forward-looking financial guidance.  The conference call will be hosted by Integra's senior management team and will be open to all listeners.  Additional forward-looking information may be discussed in a question-and-answer session following the call. Integra's management team will reference a presentation during the conference call, which can be found on the Investor section of the website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">investor.integralife.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Access to the live call is available by dialing 866-571-0905 and using the passcode 1121226#. A simultaneous webcast of the call will be available via the Company&#8217;s website at </font><font style="color:#009ec2;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">www.integralife.com</font><font style="color:#5e5f5e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">A webcast replay of the call can be accessed through the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Investor Relations</font><font style="color:#009ec2;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">homepage of Integra's website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">www.integralife.com</font><font style="color:#009ec2;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> A </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">replay of the call will be available until November 7, 2022 by dialing 866-583-1035 and using the passcode 1121226#.</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:13.5pt;font-weight:400;line-height:107%"> </font></div><div style="margin-bottom:6pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Integra</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, Aurora</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, Bactiseal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> BioD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, CerebroFlo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, CereLink</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> Certas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> Plus, Codman</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, CUSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, Cytal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, DuraGen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, DuraSeal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, Gentrix</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, ICP Express</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, Integra</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, Licox</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> , MAYFIELD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, MediHoney</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, MicroFrance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, MicroMatrix</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, NeuraGen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> , NeuraWrap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> , PriMatrix</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, SurgiMend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, TCC-EZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and VersaTru</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. For the latest news and information about Integra and its products, please visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">www.integralife.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like &#8220;will,&#8221; &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;might,&#8221; &#8220;possible,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#34;forecast,&#34; &#34;guidance,&#34; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#34;target,&#34; or &#8220;continue,&#8221; the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this news release include, but are not limited to, statements concerning future financial performance, including projections for revenues, expected revenue growth (both reported and organic), GAAP and adjusted net income, GAAP and adjusted earnings per diluted share, non-GAAP adjustments such as divestiture, acquisition and integration-related charges, intangible asset amortization, structural optimization charges, EU Medical Device Regulation-related charges, and income tax expense (benefit) related to non-GAAP adjustments and other items, capital return plans and expectations and plans with respect to strategic initiatives and product development.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">It is important to note that the Company&#8217;s goals and expectations are not predictions of actual performance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited, to the following&#58; the impact of COVID-19 (and any subsequent variants) and its effects on our employees, customers, patients, suppliers and distributors, including the economic impacts of the various recommendations, orders and protocols issued by governmental agencies and other regulatory bodies (including any periodic reimplementation of preventative measures in various global locations) in response to the continual evolution of the pandemic&#59; macroeconomic conditions, including inflation, disruptions to the global supply chain, fluctuations in currency exchange rates, weakness in general economic conditions and recessions&#59; the Company's ability to execute its operating plan effectively&#59; the Company&#8217;s ability to successfully integrate acquired businesses&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">the Company&#8217;s ability to achieve sales growth in a timely fashion and execute on its channel reorganization in its Tissue Technologies segment&#59; the Company's ability to manufacture and ship sufficient quantities of its products to meet its customers' demands&#59; the ability of third-party suppliers to supply us with raw materials and finished products&#59; global macroeconomic and political conditions&#59; the Company's ability to manage its direct sales channels effectively&#59; the sales performance of third-party distributors on whom the Company relies to generate revenue for certain products and geographic regions&#59; the Company's ability to access and maintain relationships with customers of acquired entities and businesses&#59; physicians' willingness to adopt and third-party payors' willingness to provide or maintain reimbursement for the Company's recently launched, planned and existing products&#59; initiatives launched by the Company's competitors&#59; downward pricing pressures from customers&#59; the Company's ability to secure regulatory approval for products in development&#59; the Company's ability to remediate quality systems violations&#59; fluctuations in hospitals' spending for capital equipment&#59; the Company's ability to comply with and obtain approvals for products of human origin and comply with regulations regarding products containing materials derived from animal sources&#59; difficulties in controlling expenses, including costs to procure and manufacture our products&#59; the impact of changes in management or staff levels&#59; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the Company's ability to leverage its existing selling organizations and administrative infrastructure&#59; the Company's ability to increase product sales and gross margins, and control non-product costs&#59; the Company&#8217;s ability to achieve anticipated growth rates, margins and scale and execute its strategy generally&#59; the amount and timing of divestiture, acquisition and integration-related costs&#59; the geographic distribution of where the Company generates its taxable income&#59; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">affecting the health care industry, including the EU Medical Devices Regulation&#59; fluctuations in foreign currency exchange rates&#59; the amount of our bank borrowings outstanding and other factors influencing liquidity&#59; and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading &#8220;Risk Factors&#8221; included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2021 and information contained in subsequent filings with the Securities and Exchange Commission.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Discussion of Adjusted Financial Measures</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization (&#34;EBITDA&#34;), adjusted net income, adjusted earnings per diluted share, free cash flow and adjusted free cash flow conversion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures and discontinuances. Adjusted EBITDA consists of GAAP net income excluding&#58; (i) depreciation and amortization&#59; (ii) other income (expense)&#59; (iii) interest income and expense&#59; (iv) income tax expense (benefit)&#59; and (v) those operating expenses also excluded from adjusted net income.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The measure of adjusted net income consists of GAAP net income, excluding&#58; (i) structural optimization charges&#59; (ii) divestiture, acquisition and integration-related charges&#59; (iii) EU Medical Device Regulation-related charges&#59; (iv) intangible asset amortization expense&#59; and (v) income tax impact from adjustments. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The measure of free cash flow consists of GAAP net cash provided by operating activities less purchases of property and equipment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Reconciliations of GAAP revenues to organic revenues and GAAP adjusted net income to adjusted EBITDA, and adjusted net income, and GAAP earnings per diluted share to adjusted earnings per diluted share all for the quarters and nine months ended September 30, 2022 and 2021, and the free cash flow and adjusted free cash flow conversion for the quarters and twelve months ended September 30, 2022 and 2021, appear in the financial tables in this release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Company believes that the presentation of organic revenues and the other non-GAAP measures provide important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this earnings press release filed today with the Securities and Exchange Commission.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">This Current Report on Form 8-K is available on the SEC's website a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> or on our website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">www.integralife.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Investor Relations Contact</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chris Ward</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(609) 772-7736</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">chris.ward&#64;integralife.com</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Media Contact&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Laurene Isip</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(609) 208-8121</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">laurene.isip&#64;integralife.com</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1a9392f145f84b03bf99691009d6f5d0_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INTEGRA LIFESCIENCES HOLDINGS CORPORATION</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except per share amounts)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.362%"><tr><td style="width:1.0%"></td><td style="width:62.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues, net</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,191&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386,861&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,445&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,468&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,736&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,831&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,820&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,010&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,141&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,113&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,142&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,422&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,049&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,439&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,264&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,809)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,192)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from sale of business</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,985&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,796&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,788&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,881&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,559&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,915&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,229&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per share</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.60</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.51</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for diluted net income per share</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.399&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,447&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues disaggregated by the major sources for the three months ended September 30, 2022 and 2021 (amounts in thousands)&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Neurosurgery</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,848&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,210&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Instruments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,948&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,287&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total Codman Specialty Surgical</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,796&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,497&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)%</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Wound Reconstruction and Care</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,625</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,744&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Private Label</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,770&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,620&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total Tissue Technologies</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,395&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,364&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total reported revenues</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,191&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386,861&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)%</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Impact of changes in currency exchange rates</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,786</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less contribution of revenues from acquisitions</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less contribution of revenues from divested products</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,125)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less contribution of revenues from discontinued products</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,004)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,149)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total organic revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font></div></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,793&#160;</font></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,587&#160;</font></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5%</font></td></tr></table></div><div style="margin-bottom:10pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Organic revenues have been adjusted to exclude foreign currency (current period), acquisitions and to account for divested and discontinued products.</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1a9392f145f84b03bf99691009d6f5d0_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Items included in GAAP net income and location where each item is recorded are as follows&#58;</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended September 30, 2022 </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.710%"><tr><td style="width:1.0%"></td><td style="width:35.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Amount</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">COGS(a)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&#38;A(b)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">R&#38;D(c)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amort.(d)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OI&#38;E(e)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax(f)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition, divestiture and integration-related charges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,841)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,151)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(547)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,320)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Structural Optimization charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,112&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,765&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,356&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU Medical Device Regulation charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,208&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,672&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,279&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,192&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,051&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,141&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated income tax impact from above adjustments and other items</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,892)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,892)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,275&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">COGS - Cost of goods sold</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">SG&#38;A - Selling, general and administrative</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">R&#38;D - Research &#38; development</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Amort. - Intangible asset amortization</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">OI&#38;E - Other income &#38; expense</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.34pt">Tax - Income tax expense (benefit)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Acquisition, divestiture and integration-related charges are associated with Arkis Biosciences, ACell acquisitions and the divestiture of Extremity Orthopedics and traditional wound care (TWC). Includes banking, legal, consulting, systems, and other income and expenses.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1a9392f145f84b03bf99691009d6f5d0_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Items included in GAAP net income and location where each item is recorded are as follows&#58;</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended September 30, 2021 </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.710%"><tr><td style="width:1.0%"></td><td style="width:35.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Amount</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">COGS(a)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&#38;A(b)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">R&#38;D(c)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amort.(d)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OI&#38;E(e)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax(f)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition, divestiture and integration-related charges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,954</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,323)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Structural Optimization charges</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,719</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,993</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,235</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,492</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU Medical Device Regulation charges</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,077</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,185</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible Asset Amortization Expense</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,248</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,135</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,113</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated income tax impact from above adjustments and other items</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,853)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,853)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,873</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">COGS - Cost of goods sold</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">SG&#38;A - Selling, general and administrative</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">R&#38;D - Research &#38; development</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Amort. - Intangible asset amortization</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">OI&#38;E - Other income &#38; expense</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.34pt">Tax - Income tax expense (benefit)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, Rebound Therapeutics and ACell acquisitions and the divestiture of Extremity Orthopedics and includes banking, legal, consulting, systems, and other income and expenses.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1a9392f145f84b03bf99691009d6f5d0_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO ADJUSTED EBITDA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:67.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP net income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,915&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,229&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and intangible asset amortization expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,467&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,121&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,972)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,432)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,545&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,406&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,881&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,559&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Structural optimization charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,112&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,719&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition, divestiture and integration-related charges(1)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,841)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU Medical Device Regulation charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,208&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,077&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total of non-GAAP adjustments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,400&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,087&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,315&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,315&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, Rebound Therapeutics and ACell acquisitions and the divestiture of Extremity Orthopedics and TWC. Includes banking, legal, consulting, systems, and other income and expenses. </font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO MEASURES OF ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except per share amounts)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:69.134%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.245%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP net income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,915&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,229&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Structural optimization charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,112&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,719&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition, divestiture and integration-related charges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,841)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU Medical Device Regulation charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,208&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,077&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,192&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,248&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated income tax impact from adjustments and other items</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,892)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,853)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total of non-GAAP adjustments</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,779&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,828&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,694&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,058&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted diluted net income per share</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.86&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.86&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for diluted net income per share</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,399&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,447&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, Rebound Therapeutics and ACell acquisitions and the divestiture of Extremity Orthopedics and TWC. Includes banking, legal, consulting, systems, and other income and expenses. </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1a9392f145f84b03bf99691009d6f5d0_16"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED BALANCE SHEET DATA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:61.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br>2021</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,937&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513,448&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,268&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,831&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,060&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,386&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current and long-term borrowing under senior credit facility</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870,780&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,257&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings under securitization facility</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term convertible securities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566,612&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,426&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</font></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724,414&#160;</font></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684,804&#160;</font></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED STATEMENT OF CASH FLOWS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</font></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:61.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,135&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,150&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,760)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,958)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used by financing activities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,254)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,747)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,632)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,380)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,511)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1a9392f145f84b03bf99691009d6f5d0_19"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP OPERATING CASH FLOW TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MEASURES OF FREE CASH FLOW AND ADJUSTED FREE CASH FLOW CONVERSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:66.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,310&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,778&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,157)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,286)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free cash flow</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,153&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,492&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,694&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,058&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted free cash flow conversion</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.3&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Twelve Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,418&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,414&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,315)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,023)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free cash flow</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,103&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,391&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,183&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,780&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted free cash flow conversion</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Adjusted net income for quarters ended September 30, 2022 and 2021 are reconciled above. Adjusted net income for remaining quarters in the trailing twelve months calculation have been previously reconciled and are publicly available in the Quarterly Earnings Call Presentations on our website at investor.integralife.com under Events &#38; Presentations.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates adjusted free cash flow conversion by dividing its free cash flow by adjusted net income.  The Company believes this measure is useful in evaluating the significance of the cash special charges in its adjusted earnings measures.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>iart-20221026.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:852baafa-ae93-41e4-ab78-70b4172d0966,g:7a16c048-5b07-4688-8d13-bd45fd1dd359-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iart="http://integralife.com/20221026" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://integralife.com/20221026">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="iart-20221026_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="iart-20221026_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="iart-20221026_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://integralife.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>iart-20221026_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:852baafa-ae93-41e4-ab78-70b4172d0966,g:7a16c048-5b07-4688-8d13-bd45fd1dd359-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://integralife.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="iart-20221026.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://integralife.com/role/DocumentandEntityInformation" xlink:type="extended" id="i6f82ccb281bf454583a23b30900eb091_DocumentandEntityInformation">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2108a965-b944-4836-a520-536226759543" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_DocumentType_2108a965-b944-4836-a520-536226759543" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a78399be-43a9-460a-a5b7-0f4a0b387f90" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_DocumentPeriodEndDate_a78399be-43a9-460a-a5b7-0f4a0b387f90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4af624b5-5967-4ad4-92eb-0985ea8c0cf8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityRegistrantName_4af624b5-5967-4ad4-92eb-0985ea8c0cf8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_377ad8ba-0775-4223-a0ad-ef2893599cc2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityIncorporationStateCountryCode_377ad8ba-0775-4223-a0ad-ef2893599cc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5c0012b5-5daf-4804-9a6a-f1218cfcd521" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityFileNumber_5c0012b5-5daf-4804-9a6a-f1218cfcd521" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e5de3911-7b8b-45cb-bae8-79dbb32095ef" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityTaxIdentificationNumber_e5de3911-7b8b-45cb-bae8-79dbb32095ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d0960f89-5158-4308-8850-cd2f6d820471" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityAddressAddressLine1_d0960f89-5158-4308-8850-cd2f6d820471" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9564f136-f80b-4f21-a6d5-4f72c188daab" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityAddressCityOrTown_9564f136-f80b-4f21-a6d5-4f72c188daab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_196977bf-ba99-489f-b8c9-cce3a181a728" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityAddressStateOrProvince_196977bf-ba99-489f-b8c9-cce3a181a728" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e94e58a4-fc86-435d-9321-7cc02d488ac8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityAddressPostalZipCode_e94e58a4-fc86-435d-9321-7cc02d488ac8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_30e01ecb-07d8-46ad-8fc8-b3e0a994c0e4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_CityAreaCode_30e01ecb-07d8-46ad-8fc8-b3e0a994c0e4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7891559f-be4f-4e8a-8ab4-acaed431ca0e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_LocalPhoneNumber_7891559f-be4f-4e8a-8ab4-acaed431ca0e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_f8cb0a97-f965-4d6b-8d83-1002fce2ef38" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_WrittenCommunications_f8cb0a97-f965-4d6b-8d83-1002fce2ef38" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_0f6a7808-e08e-4dda-8cd3-d23179bde908" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_SolicitingMaterial_0f6a7808-e08e-4dda-8cd3-d23179bde908" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_f9ed8836-2fdf-41c6-9b35-1f2699765555" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_PreCommencementTenderOffer_f9ed8836-2fdf-41c6-9b35-1f2699765555" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_c22a8191-3e45-44c3-860a-f20a8b82a43e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_c22a8191-3e45-44c3-860a-f20a8b82a43e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a89edc8b-ecbb-44f3-878a-e51e55ae384b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_Security12bTitle_a89edc8b-ecbb-44f3-878a-e51e55ae384b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ffe8af97-4bd5-48fe-9d7a-0bc8ce549196" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_TradingSymbol_ffe8af97-4bd5-48fe-9d7a-0bc8ce549196" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5c032978-063b-4c49-82e2-9a743ce5ac51" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_SecurityExchangeName_5c032978-063b-4c49-82e2-9a743ce5ac51" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3d1d30c0-80cb-4392-a621-0d60780fd946" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityEmergingGrowthCompany_3d1d30c0-80cb-4392-a621-0d60780fd946" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_49b76bcd-cbd8-41b2-bc9d-35d635c3b6c5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityCentralIndexKey_49b76bcd-cbd8-41b2-bc9d-35d635c3b6c5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_41a9ed14-1d20-4763-b054-43fcdcfc1976" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_AmendmentFlag_41a9ed14-1d20-4763-b054-43fcdcfc1976" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_5f008590-8bbe-444b-aad3-fc750b5fb7cc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntitiesTable_5f008590-8bbe-444b-aad3-fc750b5fb7cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_efbb857c-fe9b-482e-a7fe-9d130293a705" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_5f008590-8bbe-444b-aad3-fc750b5fb7cc" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_efbb857c-fe9b-482e-a7fe-9d130293a705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_efbb857c-fe9b-482e-a7fe-9d130293a705_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_efbb857c-fe9b-482e-a7fe-9d130293a705" xlink:to="loc_dei_AddressTypeDomain_efbb857c-fe9b-482e-a7fe-9d130293a705_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_99a49cea-2a97-41aa-a191-1aac962c1477" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_efbb857c-fe9b-482e-a7fe-9d130293a705" xlink:to="loc_dei_AddressTypeDomain_99a49cea-2a97-41aa-a191-1aac962c1477" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>iart-20221026_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:852baafa-ae93-41e4-ab78-70b4172d0966,g:7a16c048-5b07-4688-8d13-bd45fd1dd359-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityAddressStateOrProvince_d8e6a59b-de16-4a5f-82b9-7013ca6bb15c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_41d46e3a-0812-4b91-9f5b-8691ccd82196_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_55dea0b4-f042-47fe-ba3f-2b7964186cf7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4e7a4a81-6f28-40d7-beec-7e7ffcb85620_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_bf9ebe37-b5d6-439f-9d73-27119a841dc2_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_372b6dc3-1c3e-420f-8160-8a042cd9c028_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_2c38713a-a9e0-43d5-a105-6f9544504225_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_96c5d200-88ce-4709-9b1f-9f733f648135_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_73ec5dc3-1c36-43c8-978f-6be79d041c9e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9ed99aa5-0363-49ca-97af-6b6c97ced35f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e7307eb7-1af5-4f84-9972-12b87aa93723_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_da3dda18-2d45-4e2e-8623-ae48f3e3c36c_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ca96d181-cd90-4658-9c2b-f48ecab0eec5_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_32f9b146-0cce-4822-8cb4-5470e16e0080_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_026bd22b-099f-45bc-bf32-3fd7db4a88f0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b4b95d31-369d-43c9-ac0d-951dfb8e23c3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_8c5770d8-bc84-4af7-82fa-0b22c676077b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_6705c4c3-96bd-45a0-8eba-32b305195604_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_06eb1a6b-7aeb-46e0-ada5-e00de8a9fe70_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4a98b99f-807f-4c6f-92a5-a763cf6f95ad_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3f7d27a2-040b-485b-9b29-de34803de22c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_dae8bf75-7400-496f-97d0-69ed6d4a8b8f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_76084a92-7dca-4806-81bc-349a589db2a4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b8893f74-4ec4-4909-8e21-0268e25cd29e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_1d88cdc5-1fd7-455c-8f65-2bf33659e8e5_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_26d124a3-6ca2-4906-9a38-8a314bb87d13_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_56b527a4-fadc-4f77-b910-98d1fc650391_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>iart-20221026_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:852baafa-ae93-41e4-ab78-70b4172d0966,g:7a16c048-5b07-4688-8d13-bd45fd1dd359-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://integralife.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="iart-20221026.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://integralife.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_836b8899-4979-4a01-846c-03e47a086ebc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_5f008590-8bbe-444b-aad3-fc750b5fb7cc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_836b8899-4979-4a01-846c-03e47a086ebc" xlink:to="loc_dei_EntitiesTable_5f008590-8bbe-444b-aad3-fc750b5fb7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_efbb857c-fe9b-482e-a7fe-9d130293a705" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_5f008590-8bbe-444b-aad3-fc750b5fb7cc" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_efbb857c-fe9b-482e-a7fe-9d130293a705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_99a49cea-2a97-41aa-a191-1aac962c1477" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_efbb857c-fe9b-482e-a7fe-9d130293a705" xlink:to="loc_dei_AddressTypeDomain_99a49cea-2a97-41aa-a191-1aac962c1477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_5f008590-8bbe-444b-aad3-fc750b5fb7cc" xlink:to="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2108a965-b944-4836-a520-536226759543" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_DocumentType_2108a965-b944-4836-a520-536226759543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a78399be-43a9-460a-a5b7-0f4a0b387f90" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_DocumentPeriodEndDate_a78399be-43a9-460a-a5b7-0f4a0b387f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4af624b5-5967-4ad4-92eb-0985ea8c0cf8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityRegistrantName_4af624b5-5967-4ad4-92eb-0985ea8c0cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_377ad8ba-0775-4223-a0ad-ef2893599cc2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityIncorporationStateCountryCode_377ad8ba-0775-4223-a0ad-ef2893599cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5c0012b5-5daf-4804-9a6a-f1218cfcd521" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityFileNumber_5c0012b5-5daf-4804-9a6a-f1218cfcd521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e5de3911-7b8b-45cb-bae8-79dbb32095ef" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityTaxIdentificationNumber_e5de3911-7b8b-45cb-bae8-79dbb32095ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d0960f89-5158-4308-8850-cd2f6d820471" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityAddressAddressLine1_d0960f89-5158-4308-8850-cd2f6d820471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9564f136-f80b-4f21-a6d5-4f72c188daab" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityAddressCityOrTown_9564f136-f80b-4f21-a6d5-4f72c188daab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_196977bf-ba99-489f-b8c9-cce3a181a728" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityAddressStateOrProvince_196977bf-ba99-489f-b8c9-cce3a181a728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e94e58a4-fc86-435d-9321-7cc02d488ac8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityAddressPostalZipCode_e94e58a4-fc86-435d-9321-7cc02d488ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_30e01ecb-07d8-46ad-8fc8-b3e0a994c0e4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_CityAreaCode_30e01ecb-07d8-46ad-8fc8-b3e0a994c0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7891559f-be4f-4e8a-8ab4-acaed431ca0e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_LocalPhoneNumber_7891559f-be4f-4e8a-8ab4-acaed431ca0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_f8cb0a97-f965-4d6b-8d83-1002fce2ef38" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_WrittenCommunications_f8cb0a97-f965-4d6b-8d83-1002fce2ef38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_0f6a7808-e08e-4dda-8cd3-d23179bde908" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_SolicitingMaterial_0f6a7808-e08e-4dda-8cd3-d23179bde908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_f9ed8836-2fdf-41c6-9b35-1f2699765555" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_PreCommencementTenderOffer_f9ed8836-2fdf-41c6-9b35-1f2699765555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_c22a8191-3e45-44c3-860a-f20a8b82a43e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_c22a8191-3e45-44c3-860a-f20a8b82a43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a89edc8b-ecbb-44f3-878a-e51e55ae384b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_Security12bTitle_a89edc8b-ecbb-44f3-878a-e51e55ae384b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ffe8af97-4bd5-48fe-9d7a-0bc8ce549196" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_TradingSymbol_ffe8af97-4bd5-48fe-9d7a-0bc8ce549196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5c032978-063b-4c49-82e2-9a743ce5ac51" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_SecurityExchangeName_5c032978-063b-4c49-82e2-9a743ce5ac51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3d1d30c0-80cb-4392-a621-0d60780fd946" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityEmergingGrowthCompany_3d1d30c0-80cb-4392-a621-0d60780fd946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_49b76bcd-cbd8-41b2-bc9d-35d635c3b6c5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_EntityCentralIndexKey_49b76bcd-cbd8-41b2-bc9d-35d635c3b6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_41a9ed14-1d20-4763-b054-43fcdcfc1976" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b0816e5c-65eb-495b-9e7a-b4b3e28a27ea" xlink:to="loc_dei_AmendmentFlag_41a9ed14-1d20-4763-b054-43fcdcfc1976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140475891973264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 26,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INTEGRA LIFESCIENCES HOLDINGS CORP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-26224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">51-0317849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1100 Campus Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Princeton<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">275-0500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $.01 Per Share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IART<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000917520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>iart-20221026_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="iart-20221026.xsd" xlink:type="simple"/>
    <context id="i815e3e6206184c648e6b398062c516e3_D20221026-20221026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000917520</identifier>
        </entity>
        <period>
            <startDate>2022-10-26</startDate>
            <endDate>2022-10-26</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV80L2ZyYWc6ZDBjMDJmNTVhYzZjNDAwZGFmY2FjYjU2N2JmNWJmNzgvdGFibGU6MjI0NmZmODIyYjg2NDUwYWFkOTljOGEzNDNjOGUzYjgvdGFibGVyYW5nZToyMjQ2ZmY4MjJiODY0NTBhYWQ5OWM4YTM0M2M4ZTNiOF8yLTEtMS0xLTEzNTI0NQ_74e260f9-2010-45ce-81c4-bd6bc6c7e129">0000917520</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV80L2ZyYWc6ZDBjMDJmNTVhYzZjNDAwZGFmY2FjYjU2N2JmNWJmNzgvdGFibGU6MjI0NmZmODIyYjg2NDUwYWFkOTljOGEzNDNjOGUzYjgvdGFibGVyYW5nZToyMjQ2ZmY4MjJiODY0NTBhYWQ5OWM4YTM0M2M4ZTNiOF81LTEtMS0xLTEzNTI0NQ_e2ef3880-557e-4d7a-b872-3c05e5e340ad">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzQw_b5f13318-25d8-4db0-9155-d372aa25f9af">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18yMzM_5a06e638-ee7d-4c06-bf4e-ba702a3bde96">2022-10-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzQ2_537041c9-8b88-4009-99ac-ddeca527d403">INTEGRA LIFESCIENCES HOLDINGS CORP</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGFibGU6Y2FkZjhkZTNkOWNiNGI5YmFjNDIzZjRmYTM2Mjc2NDEvdGFibGVyYW5nZTpjYWRmOGRlM2Q5Y2I0YjliYWM0MjNmNGZhMzYyNzY0MV8wLTAtMS0xLTEzNTI0NQ_6390f7b2-8dc4-445c-992f-beef6c207243">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGFibGU6Y2FkZjhkZTNkOWNiNGI5YmFjNDIzZjRmYTM2Mjc2NDEvdGFibGVyYW5nZTpjYWRmOGRlM2Q5Y2I0YjliYWM0MjNmNGZhMzYyNzY0MV8wLTEtMS0xLTEzNTI0NQ_e96dae3c-7845-4e33-9080-9112607283b1">0-26224</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGFibGU6Y2FkZjhkZTNkOWNiNGI5YmFjNDIzZjRmYTM2Mjc2NDEvdGFibGVyYW5nZTpjYWRmOGRlM2Q5Y2I0YjliYWM0MjNmNGZhMzYyNzY0MV8wLTItMS0xLTEzNTI0NQ_79424c87-a85c-491b-9b40-a427777221e3">51-0317849</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzQ3_70d10cbe-c75c-4b2c-a096-ed3f2bd9435e">1100 Campus Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzQx_e92c44f7-7951-4652-a361-62d6ab14d5d2">Princeton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzM1_3343047e-11f4-494c-847f-b0b396ea0ad3">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzQy_d8a16384-0c70-486c-b717-6f4ba66409d9">08540</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzM2_dc4703fe-35ac-4cbd-ad63-53c52091690b">609</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzM3_379ae72c-811d-4aaa-8f30-bea4ec6d1592">275-0500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzQz_4e33a390-06b6-46c8-bc0f-7a2bcf6840b0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzM4_094ebcea-7441-402c-b234-05aff66ac7e0">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzM5_f170fb45-968a-436e-b7dc-26a823c385a0">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzQ0_f377c343-1316-4e8d-9e3a-5feb6dafa3a8">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGFibGU6NjJmODRhMjZlYmI3NGNiMzlkM2ExY2VhNjljMWIzZGUvdGFibGVyYW5nZTo2MmY4NGEyNmViYjc0Y2IzOWQzYTFjZWE2OWMxYjNkZV8xLTAtMS0xLTEzNTI0NQ_4b0977b4-a37a-4eba-b188-4cf4985c71d7">Common Stock, Par Value $.01 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGFibGU6NjJmODRhMjZlYmI3NGNiMzlkM2ExY2VhNjljMWIzZGUvdGFibGVyYW5nZTo2MmY4NGEyNmViYjc0Y2IzOWQzYTFjZWE2OWMxYjNkZV8xLTEtMS0xLTEzNTI0NQ_8b175031-6398-46a6-a1a0-bac1adfc2918">IART</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGFibGU6NjJmODRhMjZlYmI3NGNiMzlkM2ExY2VhNjljMWIzZGUvdGFibGVyYW5nZTo2MmY4NGEyNmViYjc0Y2IzOWQzYTFjZWE2OWMxYjNkZV8xLTItMS0xLTEzNTI0NQ_ccce8746-dbb0-4f0c-b291-48c522156667">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i815e3e6206184c648e6b398062c516e3_D20221026-20221026"
      id="id3VybDovL2RvY3MudjEvZG9jOjY1ZGU4OTAwY2IxNzRhNmQ4YWJkMTI2ODU4M2JiZDUxL3NlYzo2NWRlODkwMGNiMTc0YTZkOGFiZDEyNjg1ODNiYmQ1MV8xL2ZyYWc6NzhiNjFhMGYwZDYwNDE3MDk4YTBlNzAzMThhNDVlNjMvdGV4dHJlZ2lvbjo3OGI2MWEwZjBkNjA0MTcwOThhMGU3MDMxOGE0NWU2M18xNzQ1_76682b62-fdd0-4c73-a179-bfb3672983e1">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MK79GXUW%R*PXCRZD@=-M45QS!G9A&\#SI93FK6*/N.4O%(/_ %!+ P04
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MJ'7N0;#W\!J-'<V/'[?\ 5!+ P04    " #L,5I5)!Z;HJT   #X 0  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,
M75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO
M *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR
M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/
M3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ [#%:5660>9(9 0  SP,
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +
M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5
M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP
M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM
M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>
M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]
M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M" #L,5I5!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( .PQ6E6G+[U$[@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( .PQ6E697)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ [#%:58/HMNY=!   K1   !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .PQ6E6?H!OP
ML0(  .(,   -              "  : ,  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ [#%:59>*NQS     $P(   L              ( !? \  %]R96QS
M+RYR96QS4$L! A0#%     @ [#%:51PX9>H_ 0  / (   \
M ( !91   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .PQ6E4D'INBK0
M /@!   :              "  =$1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( .PQ6E5ED'F2&0$  ,\#   3              "
M ;82  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(    4
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="iart-20221026.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://integralife.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="iart-20221026.htm">iart-20221026.htm</File>
    <File>ex991-q32022earningsrelease.htm</File>
    <File>iart-20221026.xsd</File>
    <File>iart-20221026_def.xml</File>
    <File>iart-20221026_lab.xml</File>
    <File>iart-20221026_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "iart-20221026.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "iart-20221026_def.xml"
     ]
    },
    "inline": {
     "local": [
      "iart-20221026.htm"
     ]
    },
    "labelLink": {
     "local": [
      "iart-20221026_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "iart-20221026_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "iart-20221026.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 27,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "iart",
   "nsuri": "http://integralife.com/20221026",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "iart-20221026.htm",
      "contextRef": "i815e3e6206184c648e6b398062c516e3_D20221026-20221026",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://integralife.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "iart-20221026.htm",
      "contextRef": "i815e3e6206184c648e6b398062c516e3_D20221026-20221026",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]",
        "terseLabel": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]",
        "terseLabel": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://integralife.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000917520-22-000051-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000917520-22-000051-xbrl.zip
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M96XV^C#9,0O6+KZ"Z5>U^0LS;5>]8 V_6C9GUYIU"G%"T'H^&<S0_:+^"$8
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M\(:.$F_#VP1<,8I\;/U@1/5A5T]$RYQ3DOXB#M8O>-X. 79\$B&.. ?1XZW
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MU-/PEGMJ?6<%_? 0+UWPR)KI"&_ YL7-$9_[HE<@<.AQ6BF&+NO:QH%-T1J
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M<\2,"EL[V^BTD'4]ITZ6=O(*-=JS.@])C?9B?7:D1MLJM%13ZUN%E@Y0S6(
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MD0@E$J%$(I1(A!*)L#2DEDB$)4$B1'S!;N# Q&"*21A$"3P:SI1U$(4W=,!
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MKSS?)-]LX)N6HK>;1^.;"JG:#^@J,[=BZ 7WS^F,N96D%(^5&JB"C*/;V:^
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M55.Z(&M/8Z:\]T?\T/5%O=P_HT#$HG8J1X#7D;C_\^^686AO=W+= ;[I;]^
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MT7EA\HG.E 3(D.JAAFDP0]6:DP!3LFD4+NSE3>I3K:H[U?+ME1K9/!._<7+
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MW!,C.["K$U*8Y/1(J5XZYE/UAU7]P#\XHZEA/3@2/BCXP&1ZQ.V;QT6[KE'
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M;0^V&RKHKJC-]]X:<X+-;ISUG@!02P,$%     @ [#%:53M[KSOL!P  C3@
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M7IV85W.ED_G;59[D=V^4RO1Z;6:I7'_,/F7IS\3,ZG-%=<1#)H#2* (!#V-
ML6 FA2%?\D@(%,IY?G]NS_4*?/VR@U&.U6^@$XM(\P[%&K?I=28?<MURT9;
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M;^6E^?YTV9D)(Q%BP@,0<R5!$!,"!$,0,*I0+*,0^@S9/GFZ.L#49+S#Z.U
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MH[@0.\+%9%FW HOCRM?->=T,HGQ*SL"C^J+JFNNC.F NM(9@'!"JM2*2<T&
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MZ%]=?+WW/U!+ 0(4 Q0    ( .PQ6E5_M#ZYPS@  &@" P ?
M  "  0    !E>#DY,2UQ,S(P,C)E87)N:6YG<W)E;&5A<V4N:'1M4$L! A0#
M%     @ [#%:5<9W?"(G)   I]4  !$              ( ! #D  &EA<G0M
M,C R,C$P,C8N:'1M4$L! A0#%     @ [#%:51KMPL:) @  L0@  !$
M         ( !5ET  &EA<G0M,C R,C$P,C8N>'-D4$L! A0#%     @ [#%:
M53M[KSOL!P  C3@  !4              ( !#F   &EA<G0M,C R,C$P,C9?
M9&5F+GAM;%!+ 0(4 Q0    ( .PQ6E5<AI3<W@L  (]M   5
M  "  2UH  !I87)T+3(P,C(Q,#(V7VQA8BYX;6Q02P$"% ,4    " #L,5I5
M?>@/7X,'  "(.@  %0              @ $^=   :6%R="TR,#(R,3 R-E]P
<<F4N>&UL4$L%!@     &  8 E $  /1[      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
